Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02630901 · ClinicalTrials.gov registry record · Phase 1
Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis
A Phase 1 study, sponsored by Prothena Biosciences Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT02630901: Completed Phase 1 study, sponsored by Prothena Biosciences Limited.
NCT02630901 is a Phase 1 study that has completed, run by Prothena Biosciences Limited. The registered enrollment target is 48 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02630901, a Phase 1 study, has completed, sponsored by Prothena Biosciences Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This multiple ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX003 in approximately 56 patients with Psoriasis.
Interventions
- OTHER Placebo
- DRUG PRX003
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2016-03-17 |
| Est. Completion | 2018-02-28 |
| Phase | Phase 1 |
What the finished NCT02630901 record still lists
NCT02630901 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02630901 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02630901 about?
NCT02630901 is a clinical study titled "Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis". This multiple ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX003 in approximately 56 patients with Psoriasis.
What is the current status of trial NCT02630901?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2016-03-17. Estimated completion is 2018-02-28.
What interventions are being tested in trial NCT02630901?
The interventions under investigation include: Placebo (OTHER), PRX003 (DRUG).
Who is sponsoring clinical trial NCT02630901?
This trial is sponsored by Prothena Biosciences Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02630901's enrollment target sits among peer trials
48 1025th of 2000 higher than 948 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI